BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccines (Basel) 2021-04, Vol.9 (4), p.324
Hauptverfasser:	Ji, Rui-Ru, Qu, Yajin, Zhu, Hua, Yang, Yumei, Vogel, Annette B, Sahin, Ugur, Qin, Chuan, Hui, Aimin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antiviral agents Brief Report challenge study Coronaviruses COVID-19 COVID-19 vaccines efficacy Histopathology Immunization Immunogenicity Laboratory animals Lipids Lungs mRNA mRNA vaccine Proteins RNA polymerase SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Software Transgenic mice Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.
ISSN:	2076-393X 2076-393X
DOI:	10.3390/vaccines9040324